@article{6b6aafc7ee1e435f8cebb0cf33f9630c,
title = "In vivo targeting of escherichia coli with vancomycin-arginine",
abstract = "The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC towards Escherichia coli, including b-lactamase expressing Ambler classes A, B, and D, was 8 to 16 mg/ml. Addition of 8 times the MIC of V-r to E. coli was acutely bactericidal and associated with a low frequency of resistance (,2.32 × 10210). In vivo, V-r markedly reduced E. coli burden by .7 log10 CFU/g in a thigh muscle model. These data warrant further development of V-r in combatting E. coli, including resistant forms.",
keywords = "Antibiotic resistance, Arginine, Cationic peptides, Escherichia coli, Gram-negative bacteria, Multidrug resistance, Vancomycin conjugate",
author = "Neville, {Lewis F.} and Itamar Shalit and Warn, {Peter A.} and Scheetz, {Marc H.} and Jiuzhi Sun and Chosy, {Madeline B.} and Wender, {Paul A.} and Lynette Cegelski and Rendell, {Jacob T.}",
note = "Publisher Copyright: Copyright {\textcopyright} 2021 Neville et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.",
year = "2021",
month = apr,
doi = "10.1128/AAC.02416-20",
language = "אנגלית",
volume = "65",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",
}